We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Digital Scanner Optimized for Visible and Fluorescence Microscopy Applications

By LabMedica International staff writers
Posted on 05 May 2015
A new microscope scanner accessory designed to simplify digital pathology studies was introduced at a recent cancer research conference.

Leica Biosystems (Nussloch, Germany) introduced the Aperio VERSA, a combination digital pathology research scanner for brightfield, fluorescence, and FISH (fluorescence in situ hybridization) imaging, at the April 2015 American Association for Cancer Research annual meeting in Philadelphia (PA, USA). More...


The manufacturer described the Aperio VERSA, which is based on the Leica DM600 B microscope, as combining an unsurpassed optical path with precision stage registration, ensuring accurate, high resolution images for the most sophisticated multiplexing studies. Automatic switching between dedicated brightfield and fluorescent cameras ensures consistent, crisp images. The wide range of objective lenses from 1.25x to 63x, with motorized nose piece for automatic changing, enables users to readily scan slides at their ideal resolution. Furthermore, the automated oiler and oil-immersion lenses for 40x and 63x facilitates capture of the high resolution scans in batch and unattended modes.

Once scanned, the Aperio VERSA images are integrated into a comprehensive range of image analysis solutions. The system can be optimized for local, workstation-based, single user analysis, or enterprise-level, multi-user quantification. With a broad portfolio for the detection and quantification of cellular, subcellular and molecular markers in both brightfield and fluorescence, algorithms are easily tuned, so they can be tailored for specific research requirements.

“The Aperio VERSA is a breakthrough for researchers searching for an affordable solution for their diverse imaging needs,” said Puneet Sarin, vice president and general manager of Leica Biosystems’ pathology imaging business. “This combined introduction of solutions, from advanced staining, to imaging and computerized image analysis, demonstrates our commitment to provide cutting-edge technology to drive new breakthroughs in biomarker discovery. We see the Aperio VERSA and research software as valuable tools for core laboratories, bringing increased efficiency and quality to research.”

Related Links:
Leica Biosystems



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.